#Japan #Tokyo #Astellas #IZERVAY #Geographic Atrophy

Astellas Pharma to Present Advances on IZERVAY™

Astellas Pharma Inc. has exciting news for those affected by geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company is preparing to unveil significant new data regarding its innovative treatment, IZERVAY™ (avacincaptad pegol intravitreal solution), at the American Academy of Ophthalmology (AAO) Annual Meeting, taking place from October 18 to 20, 2025, in Orlando, Florida. This major event will feature findings from studies that highlight the safety and effectiveness of IZERVAY, reinforcing Astellas's commitment to improving patient outcomes in ophthalmology.

Key Data Presentation Overview

Astellas will showcase long-term results from the GATHER2 open-label extension study, which ensures the community of researchers and practitioners has access to comprehensive evidence regarding treatment safety and efficacy over an extended period. Alongside this, the company will present real-world evidence on how IZERVAY is utilized in clinical practice, providing insights into treatment patterns and patient experiences in the U.S.

Moreover, the investigations will explore a vital structure-function relationship in GA specifically concerning the integrity of the ellipsoid zone and performance under low luminance conditions. These insights represent significant strides in understanding the complexities surrounding the disease and enhance treatment decision-making.

Marci English, Senior VP of Biopharma and Ophthalmology Development at Astellas, emphasized the company's dedication to advancing the understanding of GA through continuous research. English stated, "Astellas continues to enhance insights into geographic atrophy through new data that deepen insights into disease progression and treatment. We are committed to partnering with the retina community to drive innovation that improves outcomes for patients with GA."

Upcoming Presentations at AAO 2025

Astellas has organized a series of presentations at the AAO 2025 that will shed light on the innovative approaches embedded within the IZERVAY treatment plan. Notable presentations will include:

• - Avacincaptad Pegol for GA: 3-year results from the GATHER2 Open-Label Extension Trial by A. Khanani. An integral oral presentation to understand long-term outcomes from trial participants.
• - Treatment Patterns and Safety: Insights by D. Borkar from a real-world patient experience perspective, highlighting how treatments are administered and the safety profiles observed in the broader population.
• - Ellipsoid Zone Integrity: Presented by R. Downes, this on-demand poster will delve into findings correlating the structure-function link of ellipsoid zone integrity with visual deficits experienced by patients.

These presentations are expected to enhance understanding and guide future explorations in the treatment of GA.

Understanding IZERVAY™

IZERVAY has been proven effective for treating GA in both the United States and Japan, while remaining under investigation in other regions. It is administered as an eye injection and aims to address the severe vision loss associated with GA. AMD is a principal cause of vision impairment in elderly populations, affecting central vision and significantly influencing quality of life.

The GATHER clinical trials demonstrated IZERVAY’s efficacy and safety, meeting established endpoints and providing a robust basis for regulatory approvals. Both the GATHER1 and GATHER2 trials were pivotal in showcasing the benefits of monthly 2 mg intravitreal injections, where a comprehensive participant base was evaluated to validate treatment impact.

As we approach AAO 2025, there is palpable excitement surrounding Astellas's contributions, with many looking forward to how this data may influence future treatment protocols and patient care strategies in the field of ophthalmology. Astellas remains driven by its mission to turn innovative science into value for patients facing significant health challenges, particularly in areas of high unmet medical need.

Astellas's Commitment to Innovation

Astellas Pharma is not only focused on developing treatments like IZERVAY but is also committed to ongoing research and collaboration within the medical community to push the boundaries of what is possible in patient care. As the field of ophthalmology continues to evolve, Astellas stands out as a leader poised to make substantial contributions to the health and well-being of individuals grappling with vision-threatening conditions.

In conclusion, the AAO 2025 Annual Meeting promises invaluable insights, making it a highly anticipated event for the ophthalmology community, and Astellas is at the forefront, ready to share its groundbreaking findings.